Ampliphi Biosciences Corp (OTCMKTS:APHB) Can’t Find Its Direction

[[tagnumber 0]][[tagnumber 1]]The performance of Ampliphi Biosciences Corp (OTCMKTS:APHB) during the past two months has been pretty depressing. After recording some impressive gains in the second half of March we saw investor confidence dwindle away and the ticker lost nearly half its value over the course of April and May.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Initially, this month started slow, but a June 3 press release managed to spice things up a bit. About an hour before the sessions [[tagnumber 6]]APHB[[tagnumber 7]] came out with a press release announcing that its production facility in Ljubljana, Slovenia has been certified to manufacture bacteriophages under current Good Manufacturing Practices (cGMP).[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This brought an impressive 24.38% gain in Wednesday’s session and the volume that [[tagnumber 6]]APHB[[tagnumber 7]] recorded was around four times the average. After all, APHB is pretty well equipped, even for an OTC biotech. Here is what the company had to show for the first quarter of the year.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 17]] [[tagnumber 18]]cash: $16.6 million[[tagnumber 19]] [[tagnumber 18]]current assets: $17 million[[tagnumber 19]] [[tagnumber 18]]current liabilities: $2.1 million[[tagnumber 19]] [[tagnumber 18]]revenues: $102 thousand[[tagnumber 19]] [[tagnumber 18]]net loss: $14.5 million[[tagnumber 19]] [[tagnumber 28]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]And even with these numbers the market cap of [[tagnumber 6]]APHB[[tagnumber 7]], which sits at around $50 million, is still a lot smaller than that of OTC biotechs with far less to show. Still, it seems that the decent financial state and the positive news weren’t enough to provide for a longer upward run and we saw [[tagnumber 6]]APHB[[tagnumber 7]] lose 14.47% in Thursday’s session.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The company stock managed to finish the week off in the green, however. [[tagnumber 6]]APHB[[tagnumber 7]] added 11.63% to its value in Friday’s session and we saw some serious trading once again. A total of 1.54 million shares changed their owners and generated $274 thousand in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The company came out with another press release before the market opened today. APHB announced that they were to present new data on biological activity after exposure to nebulizer systems at the European Cystic Fibrosis Conference in Brussels, Belgium later this month.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]So far, it appears that the news were received well and APHB is 5.26% in the green. This, however, doesn’t mean that you should skip doing your due diligence and weighing out the risks before putting any money on the line.[[tagnumber 2]]